SIBUTRAMINE: THE MAGIC PILL TO LOSE WEIGHT AND INCREASE CARDIOVASCULAR RISKS

• DOI: 10.22533/at.ed.1593262310048

• Palavras-chave: sibutramine; Weight loss; cardiovascular risk

• Keywords: sibutramine; Weight loss; cardiovascular risk

• Abstract:

  A obesity is a complex and multifactorial condition that affects a growing number of people worldwide. While lifestyle changes such as diet and exercise are the cornerstone of obesity treatment, in some cases pharmacological treatment may be necessary. Sibutramine is a medication that has been widely used for the treatment of obesity, acting as a serotonin and noradrenaline reuptake inhibitor, resulting in appetite suppression and increased satiety. However, several clinical trials and observational studies have found significant associations between the use of sibutramine and adverse cardiovascular effects, including increased blood pressure, heart rate and risk of cardiovascular events such as myocardial infarction and stroke. In light of the side effects of sibutramine, many countries have suspended the marketing of this medication, restricting its use only to extreme cases of obesity. Nowadays, the most commonly used medications for the treatment of obesity include orlistat, liraglutide and phentermine/topiramate, which have a lower risk of adverse cardiovascular effects. In summary, pharmacological treatment of obesity may be an option for patients with severe obesity who have not been successful with lifestyle changes. However, it is essential to carefully evaluate the risks and benefits of each medication before prescribing it, taking into account the patient's comorbidities and clinical conditions. Sibutramine, despite its efficacy in weight control, should be used with caution due to its adverse cardiovascular effects.